Related Experiment Video
Updated: Feb 13, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to
Hope Cottrill1, Stephanie Cason1, Scott Caroen2
1Baptist Health, Lexington, KY, USA.
Abstract:
This case report describes the clinical course of a heavily pretreated patient enrolled on the Phase II QUADRUPLE THREAT clinical trial (NCT02489903) with recurrent metastatic epithelial ovarian cancer that was previously treated with a platinum doublet and that benefited from another reintroduction of a platinum doublet after a brief priming period with RRx-001. Platinum-taxane combination is the initial treatment of choice in ovarian cancer and the "go-to regimen" for patients with recurrent, platinum-sensitive disease. However, platinum resistance is an inevitable and uniformly fatal development. One of the "Holy Grails" in ovarian cancer, besides early detection, is to reverse this resistance and retreat with a platinum doublet regimen. Because of the correlation between therapeutic resistance and poor clinical outcomes, this case, which potentially demonstrates a new avenue of anticancer development in epithelial ovarian cancer provided it is repeatable with other ovarian patients, was felt to merit a report.
Related Concept Videos
Partial Fractions
Ovarian Cycle
Mixtures of Gases: Dalton's Law of Partial Pressures and Mole Fractions
Dalton's Law of Partial Pressure
Dosage Regimens: Partial Pharmacokinetic Parameters
Integration of Rational Functions Using Partial Fractions

